Doctor Calls for Meningitis B Catch-Up Jabs for All UK Teens Born Before 2015

Why It Matters

Unvaccinated teens face heightened risk of severe meningitis B, threatening public health and pressuring the NHS to reconsider its immunisation strategy.

Key Takeaways

• MenB accounts for over 80% of UK meningitis cases.
• Teens born before Sep 2015 lack NHS MenB protection.
• Kent outbreak killed two, sickened eleven.
• Private MenB vaccine costs £220‑£360 for two doses.
• GP urges NHS catch‑up program for unvaccinated cohort.

Pulse Analysis

Meningitis B has become the dominant cause of invasive meningitis in the United Kingdom, now responsible for more than 80% of cases. The recent outbreak in Kent, linked to crowded nightlife venues and rapid transmission through shared vaping devices, underscored how easily the bacterium spreads among teenagers and young adults. With two fatalities and eleven severe illnesses, the incident has reignited public concern over a vaccine gap that left an entire generation vulnerable.

The NHS introduced the MenB vaccine for newborns on 1 September 2015, but anyone born earlier missed the routine dose. Health officials have cited cost and the perceived rarity of outbreaks as reasons for not extending free vaccination to this older cohort. However, the current epidemiology—where MenB now eclipses other serogroups—challenges that logic. Private vaccination, while available at pharmacies such as Boots and Superdrug, carries a price tag of £220‑£360 for the full two‑dose regimen, creating a financial barrier for many families.

For parents, the situation demands proactive steps: checking NHS app records, consulting red books, or contacting GP practices to confirm a child’s immunisation status. The growing call from clinicians like Dr Lynch for a national catch‑up programme reflects broader pressures on the NHS to adapt its preventive health policies. Implementing a publicly funded MenB catch‑up could curb future outbreaks, reduce healthcare costs associated with severe cases, and restore confidence in the UK’s vaccination framework.